Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845517 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study TO Evaluate Efficacy AND Safety OF PF-06700841 IN Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT03845517 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 350 participants.
The verdict
NCT03845517, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
Interventions
- DRUG Placebo
- DRUG PF-06700841 15 mg
- DRUG PF-06700841 30 mg
- DRUG PF-06700841 45 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845517
The ClinicalTrials.gov registry entry for NCT03845517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03845517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03845517 about?
NCT03845517 is a clinical study titled "A Dose-ranging Study TO Evaluate Efficacy AND Safety OF PF-06700841 IN Systemic Lupus Erythematosus (SLE)". Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
What is the current status of trial NCT03845517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2019-04-18. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT03845517?
The interventions under investigation include: Placebo (DRUG), PF-06700841 15 mg (DRUG), PF-06700841 30 mg (DRUG), PF-06700841 45 mg (DRUG).
Who is sponsoring clinical trial NCT03845517?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.